clinical impact of atm and tp53 mutations in mantle cell lymphoma
Published 5 years ago • 256 plays • Length 1:15Download video MP4
Download video MP3
Similar videos
-
2:16
treating tp53 mutant mantle cell lymphoma in the boven trial
-
2:26
impact of allelic state on os in tp53-mutant aml and hr-mds
-
1:27
tp53-aberrant mcl: challenges and treatment approaches
-
2:37
the changing role of autosct in mantle cell lymphoma: the impact of novel agents
-
5:06
trials of interest in the mantle cell lymphoma space at ash 2023
-
0:44
unmet needs in aml: tp53 mutations and maintenance therapy
-
2:09
the optimal sequencing of novel therapies in mantle cell lymphoma
-
5:15
the promise of immunotherapies in t-cell lymphoma
-
40:47
mantle cell lymphoma
-
31:59
cancer immunotherapy research updates panel at 2019 cri immunotherapy patient summit in boston
-
53:53
mantle cell lymphoma case
-
0:58
therapies under investigation for mantle cell lymphoma
-
1:59
depth of molecular response in patients with tp53m mds & aml treated with magrolimab and azacitidine
-
1:38
the importance of targeting tp53 in aml and agents being explored
-
1:27
treatment options for patients with tp53-mutated aml
-
3:19
an overview of novel treatment approaches in tp53-mutated aml
-
1:33
the current guidelines and therapies for tp53-mutated mds and aml
-
2:48
the promise of pyruvate kinase activators, such as mitapivat, for treating scd and thalassemia
-
6:32
pathobiology and clinical management of t-cell lymphoma
-
3:05
the clinical use of circulating tumor dna in t-cell lymphomas
-
3:34
effect of time to relapse on os in mcl following autohct
-
1:38
dr. shah discusses p53-mutated mantle cell lymphoma